Open AccessNeuroimaging correlates of Stages of Objective Memory Impairment (SOMI) system
Author(s) -
Grober Ellen,
Papp Kathryn V.,
Rentz Dorene M.,
Sperling Reisa A.,
Johnson Keith A.,
Amariglio Rebecca E.,
Schultz Aaron,
Lipton Richard B.,
Ezzati Ali
Publication year - 2021
Publication title -
alzheimer's and dementia: diagnosis, assessment and disease monitoring
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.497
H-Index - 37
ISSN - 2352-8729
DOI - 10.1002/dad2.12224
Subject(s) - alzheimer's disease neuroimaging initiative , neurodegeneration , entorhinal cortex , neuroimaging , memory impairment , magnetic resonance imaging , biomarker , atrophy , dementia , positron emission tomography , neuroscience , psychology , amyloid (mycology) , alzheimer's disease , hippocampal formation , medicine , oncology , disease , pathology , cognition , biology , radiology , biochemistry
To assess the relationship between memory performance defined by the Stages of Objective Memory Impairment (SOMI) system and the Alzheimer's disease (AD) ATN (amyloid beta [A], pathologic tau [T], and neurodegeneration [N]) biomarker system. Methods We used data from the Harvard Aging Brain Study cohort to estimate the level of ATN biomarkers: amyloid beta (C‐Pittsburgh compound B‐positron emission tomography [PET]), tau (F‐18–flortaucipir [FTP] PET), and neurodegeneration (magnetic resonance imaging volumetrics). We assessed the cross‐sectional relationship of SOMI classification with global amyloid levels, entorhinal and inferior temporal tau deposition, and hippocampal atrophy. Results Participants with both memory storage and retrieval deficits (SOMI‐3, ‐4) had smaller hippocampal volumes and higher entorhinal and inferior temporal tau burden than participants with no memory impairment (SOMI‐0) or mild retrieval difficulty (SOMI‐1). Amyloid burden did not differ among SOMI stages. Discussion This pilot supports the close relationship between tau pathology and memory impairment across the AD continuum. SOMI may be useful to determine eligibility for randomized controlled trials prior to the assessment of biomarker status.